Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naive patients with metastatic castration-resistant prostate cancer
Cancer Chemotherapy and Pharmacology, 07/05/2012
Mardjuadi F et al. – Three–weekly docetaxel and prednisone could be combined with sorafenib at 400mg BID on days 1–21 without reaching Maximal tolerated dose (MTD). However, the authors observed a pharmacokinetic interaction between sorafenib and docetaxel, associated with significant toxicities, raising concerns about the safety of this combination in metastatic castration–resistant prostate cancer (mCRPC).